To provide a new MMP (matrix metalloprotease)-3 inhibitor which has an excellent MMP-3-inhibiting activity and is useful as a medicine capable of efficiently preventing and treating diseases such as chronic articular rheumatism, hypertrophic arthritis, diabetic ulcer, decubitus, ulcerative colitis, duodenal ulcer, dermatitis herpetiformis, and cancer.
This MMP-3 inhibitor is characterized by containing a propenohydroxamic acid derivative represented by general formula (1) [R1 is H, an alkyl, or the like; R2 is a cycloalkyl, an aryl which may have one or more substituents, or the like; R3 is H or a halogen; R4 is H or an alkyl which may have one or more substituents; R5 is R6CO, R6SO2, R6CONH, or R6CSNH (R6 is an alkyl or cycloalkyl which may have one or more substituents, or the like); R7 is H or a protecting group; A is CH or N] or its salt.
NISHIMURA KOJI
KATAYAMA KIMIKO
TAMURA KOICHI
AMANO HIROTAKA
SUGIMOTO KAORI
